QPCT CRISPR/Cas9 KO Plasmid (h): sc-405768
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- QPCT CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the QPCT genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: QPCT Antibody (4E11): sc-517122
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
QPCT CRISPR/Cas9 KO Plasmid (h) | sc-405768 | 20 µg | $397.00 |
Overview
QPCT (glutaminyl-peptide cyclotransferase) is a secreted and Golgi-associated enzyme that catalyzes N-terminal pyroglutamate formation on proteins and peptides, a post-translational modification that can influence proteolytic stability, receptor interactions, and peptide bioactivity. By converting N-terminal glutamine or glutamate residues to pyroglutamate, QPCT contributes to protein maturation within the secretory pathway and modulates extracellular signaling contexts. This activity intersects with pathways governing peptide hormone and neuropeptide processing, extracellular proteostasis, and regulated secretion. Altered pyroglutamylation has been linked in the literature to protein aggregation and neurodegeneration-associated peptide modification, supporting QPCT as a mechanistic node for studying disease-relevant proteoform biology.
QPCT CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the QPCT gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the QPCT together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the QPCT open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish QPCT protein expression.
This CRISPR knockout system enables efficient generation of QPCT-deficient cell models for investigation of QPCT signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting QPCT exon(s) critical for QPCT function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple QPCT genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by QPCT CRISPR/Cas9 KO Plasmid (h) and QPCT CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the QPCT locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by QPCT HDR Plasmid (h) and QPCT HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by QPCT homology arms to support homology-directed repair at defined QPCT target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.